Patient advisory board for inclusive cancer research
Part of Blood & lymphatic, Cancer clinical trials.
This study is about forming a community advisory board (a group of patients and researchers) to help make cancer research at Dana-Farber more inclusive and fair. It is not a treatment trial—instead, you would review study materials and give your perspective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must speak English fluently (because trial materials are in English).
- You need to be a DFCI patient with a blood cancer in remission (preferred), or a DFCI investigator (not on the research team).
- You must be willing to give oral consent (not written).
- You must agree to keep the reviews and trial materials confidential.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is beta-testing a new app designed to reduce healthcare disparities among people admitted to the hospital with suspected acute leukemia. Your feedback could help make the app more helpful for future patients.
This study collects blood samples to “test and store” (bank) information that may help doctors understand cancer in the future. You might be able to join if you’re an adult with confirmed cancer or a higher-than-usual risk for cancer.
This trial tests if a special tool can help adults aged 60 and older who are newly visiting a blood cancer or bone marrow transplant clinic understand their options and make decisions that fit their needs.
This study tests a program to help patients and their doctors work together to set a plan for each visit. If you have advanced ovarian cancer and are getting chemotherapy at Dana-Farber, you may be able to join.
This study collects information and blood samples to understand why cancer affects different groups of people differently. By joining, you help researchers find better ways to prevent and treat cancer for everyone.
This study tests a new way to check how blood cancers respond to immunotherapy. It looks at small blood or bone marrow samples before and during treatment to help doctors choose the best therapy.
Hear when a new Blood Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.